ProShares Ultra Nasdaq Biotechnology Rating $55.87 +1.07 (+1.95%) Closing price 08/15/2025 03:58 PM EasternExtended Trading$55.88 +0.02 (+0.03%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.66Holdings in BIB have an aggregate rating of Moderate Buy based on 357 analyst ratings issued in the past year covering 19 companies (39.0% of the portfolio).BIB Aggregate Price Target$55.87High Prediction$55.87Average Prediction$55.87Low Prediction$55.87Holdings in BIB have an aggregate price target of $55.87 and a range of $55.87 to $55.87 covering 19 companies (39.0% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy10 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.10%AMGNAmgen$296.47+2.1%4.6655 of 5 stars2.33$303.76 2.5%21Trending NewsAnalyst Revision5.09%VRTXVertex Pharmaceuticals$392.79+0.6%4.9487 of 5 stars2.56$497.10 26.6%27Positive News5.06%GILDGilead Sciences$118.37-0.5%4.8496 of 5 stars2.80$114.82 -3.0%25Positive NewsDividend AnnouncementAnalyst Revision4.10%REGNRegeneron Pharmaceuticals$580.41+2.6%4.8391 of 5 stars2.81$829.65 42.9%26News CoveragePositive NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionGap Up2.97%AZNAstraZeneca$79.17+0.9%2.9404 of 5 stars2.80$86.00 8.6%5Trending NewsAnalyst Revision2.59%ALNYAlnylam Pharmaceuticals$448.91+1.4%4.2504 of 5 stars2.85$405.33 -9.7%26Positive NewsInsider Trade1.47%SMMTSummit Therapeutics$26.69+0.9%2.5605 of 5 stars2.79$35.00 31.1%14News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst Revision1.33%BIIBBiogen$138.60+2.7%4.8616 of 5 stars2.34$185.74 34.0%32Analyst Forecast1.31%INSMInsmed$127.80+0.0%4.1134 of 5 stars2.94$129.57 1.4%16Trending NewsAnalyst ForecastAnalyst Revision1.29%ARGXargenex$653.83+0.2%3.9586 of 5 stars3.10$746.81 14.2%20Positive News1.20%ILMNIllumina$100.11+0.0%4.5326 of 5 stars2.25$124.58 24.4%20Analyst Downgrade1.07%RPRXRoyalty Pharma$36.35-0.4%4.9845 of 5 stars3.33$48.00 32.0%3Positive News0.98%SNYSanofi$49.77+1.5%3.9575 of 5 stars3.11$62.00 24.6%9Trending News0.95%UTHRUnited Therapeutics$313.13+0.3%4.9275 of 5 stars2.69$382.00 22.0%13Positive NewsAnalyst Forecast0.94%INCYIncyte$86.92+0.9%4.6547 of 5 stars2.33$81.20 -6.6%18Trending News0.91%MRNAModerna$28.02+5.0%4.3973 of 5 stars2.04$43.59 55.6%24Options Volume0.91%NBIXNeurocrine Biosciences$132.90+1.2%4.8558 of 5 stars2.86$160.90 21.1%220.89%MEDPMedpace$457.85-0.2%4.3122 of 5 stars1.93$406.60 -11.2%14Positive News0.86%EXELExelixis$38.31-0.4%4.9043 of 5 stars2.55$44.06 15.0%22Positive NewsAnalyst Forecast This page (NASDAQ:BIB) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access